RIGL
Rigel Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
4.72 / 10
Netural
Liquidity flow is robust (7.71/10), with positive trends across block, small, medium, large, and extra-large orders, hinting at underlying institutional interest. Analyst sentiment is mixed—50% Neutral and 50% Strong Buy across two analysts—but the historical win-rate is variable (0% for Cantor Fitzgerald, 100% for Jefferies). Together, the fund-flow is supportive, while analyst conviction remains divided, keeping the overall sentiment neutral.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-05
InstitutionJefferies
Times predicted1
Historical Win Rate100.0%
What is the analyst consensus for RIGL?
- RIGL holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.72/10 (Netural).
